Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates

Table 1

Patients’ characteristics and outcomes.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Age (years)	43	42	72	56	63	39
Gender	Male	Female	Male	Female	Male	Female
Race	Caucasian	Caucasian	Caucasian	Black	Caucasian	Caucasian
Time on dialysis at initiation of antiviral therapy (months)	4	8	9	60	9	5
Previous kidney transplantation	Yes	Yes	No	Yes	No	Yes
Previous antiviral treatment	Partial responder	Partial responder	Partial responder	Partial responder	Naïve	Relapser
HCV genotype	1	1a	1	1b	1b	1b
Initial HCV RNA concentration (log IU/mL)	4.3	5.63	6.55	5.52	5.8	5.36
Liver fibrosis at the initiation of viral therapy	F2	F2	—	F2	F1	F1-F2
Rapid virological response	Yes	No	Yes	Yes	Yes	Yes
Undetectable viremia at the end of therapy	Yes	No	No	No	Yes	Yes
Sustained virological response	Yes	No, stopped therapy at week 28	No, breakthrough between weeks 24 and 48	No, breakthrough between weeks 24 and 48	No, relapse at six months after ceasing therapy	No, relapse at one month after ceasing therapy
Decrease in Peg-IFN dose	No	Yes	Yes	Yes	No	No
Decrease in ribavirin dose	No	No	No	Yes	No	No
Decrease in boceprevir dose	No	Yes	No	Yes	No	No
Concomitant therapy	Amlodipine, bisoprolol, furosemide, calcium, and darbepoetin	Amlodipine, valsartan; furosemide, calcium, omeprazole, and darbepoetin	Irbesartan, aspirin, atenolol, simvastatin, and calcium	Calcium, aspirin, omeprazole, and levothyroxine	Simvastatin, amlodipine, and valsartan	Calcium, sevelamer carbonate, alfacalcidol, urapidil, and darbepoetin
Long-term outcome	Had received a kidney transplant at 12 months after the end of therapy and was still not viremic at 4 months after transplantation	Still viremic and on a waiting list	Deceased or on a waiting at list 3 months after antiviral therapy was stopped	Still viremic on a waiting list	Had received a kidney transplant at 1 month after HCV relapse from a HCV-positive donor and was still viremic at 6 months after kidney transplantation	Had received a kidney transplant at 8 months after HCV relapse and was still viremic at 5 months after kidney transplantation

HCV: hepatitis C virus.
Undetectable HCV RNA at week 4; undetectable HCV RNA at 24 weeks after antiviral therapy was completed.